Essilor's Stellest® lenses have been named as one of TIME’s Best Inventions of 2026 in the Health & Wellness category.
The TIMErecognition comes just over a year after the FDA granted De Novo market authorization to Stellest® lenses in September 2025, making them the first and only FDA market-authorized spectacle lenses in the US to slow myopia progression in children. The lenses also received FDA Breakthrough Device designation in 2021.
“[This] is a strong acknowledgment of Essilor’s innovation capabilities,” said Arnaud Ribadeau Dumas, Head of Product & Marketing Optical Categories at EssilorLuxottica. “We are bringing families evidence-based innovation they can trust, helping them act early on childhood myopia and support children’s visual future, today and over the long term.”
Myopia is one of the fastest-growing vision challenges among children globally. Beyond the need for clear vision today, progressive myopia can affect long-term eye health, making regular eye exams and professional guidance essential.
